Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?

Novo Nordisk (NVO) shares have risen 5.8% in a week, driven by Parvus Asset Management building a stake and positive amycretin pipeline updates, with phase III trials planned for Q1 2026; CVS Caremark also named Wegovy its preferred GLP-1 therapy. NVO is expanding its obesity pipeline amid rising competition from Eli Lilly, Amgen, and Viking Therapeutics, though past pipeline setbacks and Medicare coverage limitations present challenges. While Wegovy revenues surged 83% in Q1 2025, investors should consider both the company's strengths in semaglutide and increasing competition before adjusting their positions.

Analysis

Novo Nordisk (NVO) shares experienced a 5.8% increase over the past week, driven by activist hedge fund Parvus Asset Management acquiring a stake and positive news regarding its next-generation obesity candidate, amycretin, which is slated to enter Phase III development in Q1 2026 for both subcutaneous and oral administration. This development is part of NVO's strategy to defend its leading position in the obesity market, further supported by CVS Caremark designating Wegovy as its preferred GLP-1 therapy effective July 1 and partnerships like with Hims & Hers Health to offer discounted Wegovy. Despite these positive developments, the stock has underperformed year-to-date, losing 7.2% compared to the industry's 2.5% growth, and has fallen 26.1% in the past six months due to previous pipeline setbacks, such as disappointing data from CagriSema late-stage studies where weight loss was lower than expected, and regulatory hurdles like Medicare's decision not to cover weight-loss drugs. NVO's core strength remains its semaglutide franchise (Wegovy, Ozempic, Rybelsus), with Wegovy revenues surging 83% to DKK 17.4 billion in Q1 2025 and the company commanding a 33.3% global diabetes value market share and 54% in the GLP-1 segment. NVO is actively pursuing label expansions for semaglutide in cardiovascular disease and chronic kidney disease, with an FDA decision on a 25mg oral semaglutide for obesity expected by year-end. However, competition is intensifying, particularly from Eli Lilly's Mounjaro and Zepbound, and emerging candidates from Amgen (MariTide) and Viking Therapeutics (VK2735), in an obesity market projected to reach $100 billion by 2030. NVO trades at a forward P/E of 18.99, a premium to the industry's 15.64 but below its five-year mean of 29.25, with 2025 and 2026 earnings estimates recently revised upwards to $3.84 and $4.64 per share, respectively, and boasts a strong ROE of 80.95%.

Key Decisions for Investors

• Investors should acknowledge the recent positive catalysts for Novo Nordisk, such as the amycretin Phase III advancement and the Parvus stake, but balance this with the stock's significant 26.1% decline over the past six months due to previous pipeline and regulatory setbacks.
• Long-term investors might consider holding NVO, given robust Wegovy sales growth (83% in Q1 2025), dominant market share in GLP-1s (54%), ongoing semaglutide label expansion efforts, and a promising next-generation pipeline including amycretin and CagriSema.
• Caution is advised for new or short-term investors due to heightened competition from Eli Lilly, Amgen, and Viking Therapeutics, the impact of past clinical trial disappointments like CagriSema's lower-than-expected efficacy, and current Medicare non-coverage of weight-loss drugs, which could induce near-term volatility.
• Key developments to monitor include the FDA's decision on oral semaglutide for obesity by year-end, the initiation and progress of amycretin's Phase III trials (Q1 2026), competitive advancements especially in oral GLP-1 therapies, and any shifts in payer coverage for obesity treatments.
• While NVO's forward P/E of 18.99 is above the industry average, it remains below its historical five-year mean, and with upward revisions in 2025 and 2026 EPS estimates, investors should carefully weigh the growth outlook against the current valuation and recent stock underperformance.